Access to AD109 During FDA Review
AD109 is currently under FDA review and is not yet approved or commercially available, so you cannot obtain it outside of participation in a clinical trial. The medication is investigational and has completed Phase 3 trials (SynAIRgy and LunAIRo) but has not received FDA approval for obstructive sleep apnea treatment 1, 2.
Current Status and Access Options
AD109 (aroxybutynin 2.5 mg + atomoxetine 75 mg) is an investigational combination therapy designed to target the neuromuscular dysfunction underlying OSA by counteracting sleep-related withdrawal of noradrenergic drive and REM-related muscarinic inhibition at the hypoglossal motor nucleus 3, 4.
How to Potentially Access AD109:
Clinical Trial Participation:
- Check ClinicalTrials.gov for any ongoing or recruiting studies
- The Phase 3 trials (NCT05813275 and NCT05811247) have completed enrollment 2
- Contact Apnimed directly to inquire about expanded access programs or compassionate use protocols
Expanded Access/Compassionate Use:
- If you have severe OSA and cannot tolerate PAP therapy, your physician may be able to request expanded access from the manufacturer
- This requires documentation that you have no comparable alternative treatment options
- The FDA must also authorize such access under specific circumstances
Standard Treatment While Waiting
Since AD109 is not yet available, current evidence-based management should follow established guidelines 5:
First-line therapy:
- CPAP remains the gold standard with strong evidence for reducing AHI and improving oxygenation 5
- Weight loss if overweight/obese (strong recommendation) 5
Alternative options if CPAP intolerant:
- Mandibular advancement devices (weak recommendation, but viable alternative) 5
- Hypoglossal nerve stimulation for appropriate candidates 6
Important Caveat:
The individual components of AD109 (atomoxetine and oxybutynin) are FDA-approved medications but not for OSA treatment. Atomoxetine is approved only for ADHD 7, and using these medications off-label for OSA would be:
- Not evidence-based as monotherapy or in different combinations
- Potentially unsafe without the specific dosing and monitoring protocols used in clinical trials
- Not supported by current guidelines, which note insufficient evidence for pharmacologic agents in OSA 5
Do not attempt to replicate AD109 by obtaining the individual components separately - the specific combination, dosing, and safety profile have only been studied in the investigational formulation.